MedDataX Logo

Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

NCT ID: NCT05303961

Last Updated: 2022-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-07

Study Completion Date

2016-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study consists of Part 1 followed Part 2.

Part 1 The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of a single oral dose of SA001 and active comparator(Rebamipide) in healthy male volunteers.

Part 2 The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of multiple oral dose of SA001 in healthy male volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Part 1(Single dose, dose escalation study, SA001 240mg\~1,080mg dose group)

The starting dose is SA001 240mg, and the maximum dose is 1,080mg. Each dose group is assigned to Experimental group (SA001 or SA001 + Active Comparator(Rebamipide)) or Placebo group in a ratio of 3:1. The pharmacokinetics, safety and tolerability of SA001 and its metabolite are investigated after a single oral administration.

Part 2 (Multiple dose, dose escalation study, SA001 360mg\~1,080mg dose group)

The starting dose is SA001 360mg, and the maximum dose is 1,080mg. Each dose group is assigned to SA001 or Placebo in a ratio of 3:1. The pharmacokinetics, safety and tolerability of SA001 and its metabolite are investigated after a multiple oral administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SA001

Part 1: 24 subjects are assigned to single dose groups(240mg, 480mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1:1 and receiving each dose of SA001 in the period 1.

Part2: 18 subjects are assinged to multiple dose groups(360mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1 and receiving each dose of SA001.

Group Type EXPERIMENTAL

SA001 240mg + Rebamipide 200mg or Placebo

Intervention Type DRUG

Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo

SA001 480mg or Placebo

Intervention Type DRUG

Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)

SA001 710mg + Rebamipide 600mg or Placebo

Intervention Type DRUG

Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)

SA001 1,080mg or Placebo

Intervention Type DRUG

Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)

SA001 360mg or Placebo

Intervention Type DRUG

Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)

SA001 720mg or Placebo

Intervention Type DRUG

Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)

SA001 1,080mg or Placebo

Intervention Type DRUG

Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)

Rebamipide

Part 1: 12 subjects are assigned to single dose groups(200mg, 600mg of Rebamipide) in a ratio of 1:1 and receiving each dose of Rebamipide in the period 2.

Group Type ACTIVE_COMPARATOR

SA001 240mg + Rebamipide 200mg or Placebo

Intervention Type DRUG

Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo

SA001 710mg + Rebamipide 600mg or Placebo

Intervention Type DRUG

Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)

Placebo

Part 1: 8 subjects receiving a single dose of Placebo in the period 1.

Part2: 6 subjects receiving multiple dose of Placebo.

Group Type PLACEBO_COMPARATOR

SA001 240mg + Rebamipide 200mg or Placebo

Intervention Type DRUG

Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo

SA001 480mg or Placebo

Intervention Type DRUG

Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)

SA001 710mg + Rebamipide 600mg or Placebo

Intervention Type DRUG

Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)

SA001 1,080mg or Placebo

Intervention Type DRUG

Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)

SA001 360mg or Placebo

Intervention Type DRUG

Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)

SA001 720mg or Placebo

Intervention Type DRUG

Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)

SA001 1,080mg or Placebo

Intervention Type DRUG

Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SA001 240mg + Rebamipide 200mg or Placebo

Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo

Intervention Type DRUG

SA001 480mg or Placebo

Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)

Intervention Type DRUG

SA001 710mg + Rebamipide 600mg or Placebo

Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)

Intervention Type DRUG

SA001 1,080mg or Placebo

Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)

Intervention Type DRUG

SA001 360mg or Placebo

Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)

Intervention Type DRUG

SA001 720mg or Placebo

Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)

Intervention Type DRUG

SA001 1,080mg or Placebo

Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 19 years to 45 years (Healthy male Korean)
2. Body weight of 55 to 90kg; and BMI of 18.0 to 27.0 kg/m2
3. Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study

Exclusion Criteria

1. Subject with a disease history of any clinically significant condition as below.

\- Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc.
2. Subject with a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendicectomy or hernia surgery) that may affect the absorption of the study drug
3. Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.)
4. Serum ALT(SGPT)/AST(SGOT) \>1.5×institutional upper limit normal (ULN)
5. eGFR\< 90mL/min/1.73m2
6. Systolic blood pressure \<100 mmHg or \>160 mmHg
7. Diastolic blood pressure \<60 mmHg or \>100 mmHg
8. Inadequate cardiac function confirmed by 12-lead ECG findings at screening as followings:

* QTcF \> 430msec (males)
* PR interval \> 200msec or \< 110msec
* QRS complex \> 120msec
* Evidence of 2nd- or 3rd-degree atrioventricular (AV) block
* Pathologic Q waves (defined as Q-wave \> 40msec or depth \> 0.5mV)
* Evidence of ventricular preexicitation, left bundle branch block (LBBB), right bundle branch block (RBBB, Incomplete RBBB)
9. Subject with risk factors for Torsade de pointes such as long QT syndrome, family history of sudden death, heart failure, hypokalemia, and arrhythmias
10. Subject with a history of drug abuse within 60 days prior to screening or who is positive for drugs of abuse in urine tests at screening
11. Subject who received any drugs such as

* Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products
* Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products
12. Subject who received other investigational products within 90 days prior to the first administration of the investigational products
13. Subject who have donated whole blood within 60 days prior to the first administration of the investigational products, or donated component blood or have received blood transfusion within 30 days prior to the first administration of the investigational products
14. Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period
15. Subject with history of smoking within 90 days prior to the first administration of the investigational products
16. Subject who cannot prohibit grapefruit/ caffeine-containing foods during the study period from 3 days before the first administration of the investigational products
17. Man of reproductive potential not willing to use contraceptive measures during the study period
18. Subject not eligible for study participation in the opinion of the investigator
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SJSA001_02

Identifier Type: -

Identifier Source: org_study_id